LDN Pharma Limited

11 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

May 2034

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jul 30, 2027
The maintenance fee for Assay to Identify Anti-Cancer Agents (US 11,885,796) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,895,438	Treatment of cancer with naltrexone In force Term ends May 12, 2034 · From the USPTO record	In force	Term ends May 12, 2034	From the USPTO record
US 11,065,245	Priming of cancer cells with low dose naltrexone In force Term ends Sep 9, 2035 · From the USPTO record	In force	Term ends Sep 9, 2035	From the USPTO record
US 12,144,807	Priming of cancer cells with low dose naltrexone In force Term ends Jul 11, 2037 · From the USPTO record	In force	Term ends Jul 11, 2037	From the USPTO record
US 11,304,943	Combination for use in the treatment of lung cancer In force Term ends Mar 28, 2038 · From the USPTO record	In force	Term ends Mar 28, 2038	From the USPTO record
US 11,351,165	Agent That Increases the Expression of the Opioid Kappa 1 for the Treatment of Cancer In force Term ends Mar 28, 2038 · Medium confidence	In force	Term ends Mar 28, 2038	Medium confidence
US 12,611,405	Agent That Increases the Expression of the BCL2-ASSOCIATED Agonist of Cell Death for the Treatment of Cancer In force Ends no later than Jan 4, 2039 · Medium confidence	In force	Ends no later than Jan 4, 2039	Medium confidence
US 11,607,423	Combination of a Cannabinoid and a Chemotheraopeutic Agent for the Treatment of Breast Cancer In force Term ends May 31, 2039 · High confidence	In force	Term ends May 31, 2039	High confidence
US 12,029,737	Autoimmune Therapy In force Term ends Dec 31, 2039 · High confidence	In force	Term ends Dec 31, 2039	High confidence
US 12,324,805	Cancer Treatment In force Term ends May 17, 2040 · High confidence	In force	Term ends May 17, 2040	High confidence
US 11,885,796	Assay to Identify Anti-Cancer Agents In force Term ends Nov 19, 2040 · High confidence	In force	Term ends Nov 19, 2040	High confidence

10 of 11 patents shown.

Pro members see all 11.

Pro members: see all 11 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

10 pending · 2 no status recorded

List them